Local view for "http://purl.org/linkedpolitics/eu/plenary/2000-03-02-Speech-4-057"

PredicateValue (sorted: default)
rdf:type
dcterms:Date
dcterms:Is Part Of
dcterms:Language
lpv:document identification number
"en.20000302.4.4-057"2
lpv:hasSubsequent
lpv:speaker
lpv:spokenAs
lpv:translated text
"The amendment to the directive as presented by the Commission is an important one since it deals with a specific disease, i.e. infectious salmon anaemia, a contagious viral disease. It is a water-borne virus and is transmitted via organic substances such as blood, faecal matter, mucus, etc. There is no scientific proof of the possibility of vertical transmission of the disease through roe. It is, however, recognised that other species such as trout, eels or herring, may be carriers of the virus without being affected by it. The disease was detected in Norway in 1984 and also in Canada (1996). The virus does not survive at a temperature of more than 26° C, and is therefore not dangerous to humans. The disease chiefly affects the Scottish salmon industry. It was detected in this region in May 1998. Today, 240 salmon farms are affected by ISA. It is therefore essential to contain this disease and prevent it spreading to all the aquacultural establishments in the various Member Sates of the European Union. The Council proposal envisages setting up a system for the gradual elimination of fish affected by the disease and also a vaccination plan. We can only declare ourselves in favour of the proposed plan for the gradual elimination of affected fish. The fish farms concerned must be assisted in ‘cleaning up’ the infected site and preventing the disease from spreading through the commercial transport of live fish. As regards vaccination, we should remember that the initial directive prohibited the use of vaccines against ISA. The Commission’s new proposal would authorise the use of vaccines, but it is important to point out that so far, no vaccine has actually been found. The usefulness of this proposal is limited, to say the least, certainly in the short term. Canada does have a vaccine with a 76% success rate. Since the Canadian strain differs from the European strain, this vaccine cannot be used in its present state, but may be used as the starting point for the development of a vaccine against the European strain. It is therefore crucial for the Commission to earmark sufficient funding to support the development of an effective vaccine against the European strain of ISA."@en1

Named graphs describing this resource:

1http://purl.org/linkedpolitics/rdf/English.ttl.gz
2http://purl.org/linkedpolitics/rdf/Events_and_structure.ttl.gz
3http://purl.org/linkedpolitics/rdf/spokenAs.ttl.gz

The resource appears as object in 2 triples

Context graph